Log in
(Ad)
One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

NASDAQ:ARCT - Arcturus Therapeutics Stock Price, Forecast & News

$12.37
+0.83 (+7.19 %)
(As of 01/23/2020 05:47 AM ET)
Today's Range
$11.41
Now: $12.37
$12.46
50-Day Range
$9.82
MA: $11.06
$12.42
52-Week Range
$4.26
Now: $12.37
$15.50
Volume52,900 shs
Average Volume74,252 shs
Market Capitalization$187.28 million
P/E RatioN/A
Dividend YieldN/A
Beta2.46
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARCT
CUSIPN/A
Phone858-900-2660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.75 million
Book Value$1.27 per share

Profitability

Net Income$-21,780,000.00

Miscellaneous

Employees72
Market Cap$187.28 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive ARCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Each week, an exclusive group of investors receives access to a simple list of 3 stocks to put on their radar for the week ahead.

You can sign up today to receive access to next week's watchlist -- generated by a proprietary methodology -- at no cost or obligation.

Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Ltd (NASDAQ:ARCT) issued its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.56) EPS for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.32. The biotechnology company had revenue of $3.32 million for the quarter, compared to analyst estimates of $7.60 million. Arcturus Therapeutics had a negative return on equity of 160.16% and a negative net margin of 63.05%. View Arcturus Therapeutics' Earnings History.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Arcturus Therapeutics.

What price target have analysts set for ARCT?

5 Wall Street analysts have issued 12-month price targets for Arcturus Therapeutics' shares. Their forecasts range from $18.00 to $18.00. On average, they expect Arcturus Therapeutics' share price to reach $18.00 in the next twelve months. This suggests a possible upside of 45.5% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics.

What is the consensus analysts' recommendation for Arcturus Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics.

Has Arcturus Therapeutics been receiving favorable news coverage?

News coverage about ARCT stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arcturus Therapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Arcturus Therapeutics.

Are investors shorting Arcturus Therapeutics?

Arcturus Therapeutics saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 178,000 shares, an increase of 83.3% from the November 28th total of 97,100 shares. Based on an average daily volume of 70,400 shares, the days-to-cover ratio is currently 2.5 days. Approximately 2.4% of the shares of the company are sold short. View Arcturus Therapeutics' Current Options Chain.

Who are some of Arcturus Therapeutics' key competitors?

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Opko Health (OPK), Energy Transfer LP Unit (ET), Corbus Pharmaceuticals (CRBP), KLA (KLAC), Abeona Therapeutics (ABEO), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Terravia (TVIAQ), Corcept Therapeutics (CORT) and Exelixis (EXEL).

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the folowing people:
  • Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 47)
  • Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 40)
  • Mr. Andrew H. Sassine, CFO & Director (Age 55)
  • Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
  • Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $12.37.

How big of a company is Arcturus Therapeutics?

Arcturus Therapeutics has a market capitalization of $187.28 million and generates $15.75 million in revenue each year. The biotechnology company earns $-21,780,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.View Additional Information About Arcturus Therapeutics.

What is Arcturus Therapeutics' official website?

The official website for Arcturus Therapeutics is http://www.arcturusrx.com/.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]


MarketBeat Community Rating for Arcturus Therapeutics (NASDAQ ARCT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  338 (Vote Outperform)
Underperform Votes:  309 (Vote Underperform)
Total Votes:  647
MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Vote "Outperform" if you believe ARCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel